Tech Times on MSN
HER2-positive breast cancer trial reports 92% survival in chemo-free patients; proof pending
HER2-positive breast cancer chemotherapy can be safely omitted in about 30% of patients, five-year PHERGain trial data ...
Nanoscale particle shows potential as customizable delivery vehicle for personalized cancer vaccines
A nanoscale particle with a unique structure, developed at MIT, holds potential as a customizable delivery vehicle for personalized cancer vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results